Stryker (NYSE:SYK) Trading Up 5.2% – What’s Next?

Shares of Stryker Corporation (NYSE:SYK) shot up 5.2% during mid-day trading on Thursday . The stock traded as high as $335.86 and last traded at $332.8390. Approximately 270,023 shares traded hands during trading, a decline of 89% from the average daily volume of 2,359,955 shares. The stock had previously closed at $316.44.

Wall Street Analyst Weigh In

Several analysts recently weighed in on SYK shares. Truist Financial reissued a “hold” rating and issued a $330.00 price objective (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Leerink Partners lowered their target price on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. JPMorgan Chase & Co. cut their target price on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. The Goldman Sachs Group reiterated a “neutral” rating and issued a $361.00 price target on shares of Stryker in a research report on Friday, May 1st. Finally, Sanford C. Bernstein set a $410.00 price objective on Stryker in a research report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $392.52.

Stryker Price Performance

The firm has a market cap of $126.73 billion, a P/E ratio of 38.28, a P/E/G ratio of 1.99 and a beta of 0.77. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The business’s 50 day moving average is $311.28 and its two-hundred day moving average is $337.10.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same period last year, the company posted $2.84 EPS. The business’s revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio is presently 40.74%.

Insider Buying and Selling

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 3,500 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.45, for a total transaction of $992,075.00. Following the sale, the vice president directly owned 177 shares of the company’s stock, valued at approximately $50,170.65. This trade represents a 95.19% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 323,264 shares of company stock valued at $100,659,489 over the last 90 days. Company insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of SYK. Brighton Jones LLC grew its stake in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after buying an additional 609 shares during the period. Schnieders Capital Management LLC. acquired a new position in Stryker during the 2nd quarter worth approximately $205,000. Marshall Wace LLP boosted its holdings in Stryker by 107.9% in the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after acquiring an additional 77,831 shares in the last quarter. Nebula Research & Development LLC acquired a new stake in Stryker in the second quarter valued at approximately $219,000. Finally, HUB Investment Partners LLC acquired a new stake in Stryker in the second quarter valued at approximately $253,000. 77.09% of the stock is owned by institutional investors.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.